ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00077727
Recruitment Status : Completed
First Posted : February 16, 2004
Last Update Posted : May 24, 2011
Sponsor:
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : No date given
  Actual Study Completion Date : February 2005